Literature DB >> 7579408

Expression of stem cell factor and its receptor by human neuroblastoma cells and tumors.

D Beck1, N Gross, C B Brognara, G Perruisseau.   

Abstract

Bone marrow (BM) is a frequent site of metastasis in children with neuroblastoma (NB). Nonhematopoietic cell lines of the same neuroectodermal origin produce both stem cell factor (SCF) and its receptor, the product of the c-kit protooncogene (c-kit). Because recombinant SCF is likely to be soon clinically tested to accelerate BM recovery after high-dose chemotherapy, a treatment administered to children with disseminated NB, we addressed the question of whether SCF/c-kit complex could play a role in the proliferation and metastasis of NB cells. Northern blot analysis showed SCF mRNA transcripts in 7 of 8 (88%) NB cell lines and c-kit in 1 (13%). Neither c-kit nor SCF could be detected by Western blotting in cell extracts or by surface immunofluorescence and flow cytometry. Soluble SCF protein was detected by enzyme immunoassay at low concentrations in the cell supernatants in the same 7 NB cell lines. Treatment of 4 NB cell lines by SCF +/- cytokines relevant to BM physiology did not induce c-kit antigenic expression or modulate 3H-thymidine uptake. Likewise, the latter was not changed by incubating the cells with anti-c-kit neutralizing antibodies. Immunohistochemical analysis showed weak diffuse or focal staining for SCF and c-kit in few primary or metastatic tumor samples, only once simultaneously. We conclude that NB cell lines usually produce low levels of soluble SCF but do not express c-kit and that both proteins are rarely detected in NB tumors. The SCF/c-kit complex appears to be unlikely to stimulate NB growth or metastasis; thus, recombinant SCF could be safely administered to children with NB.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579408

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit.

Authors:  L Landuzzi; C De Giovanni; G Nicoletti; I Rossi; C Ricci; A Astolfi; L Scopece; K Scotlandi; M Serra; G P Bagnara; P Nanni; P L Lollini
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

2.  CD117 expression in glial tumors.

Authors:  Neslihan Cetin; Gerald Dienel; Murat Gokden
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

3.  No GIST-type c-kit gain of function mutations in neuroblastic tumours.

Authors:  M Korja; J Finne; T T Salmi; H Haapasalo; M Tanner; J Isola
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

4.  Poorly differentiated carcinoma of the rectum with aberrant immunophenotype: a case report.

Authors:  A Giannopoulos; I Papaconstantinou; P Alexandrou; A Petrou; A Papalambros; E Felekouras; E Papalambros
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 5.  Neuroblastoma Origin and Therapeutic Targets for Immunotherapy.

Authors:  Irina V Kholodenko; Daniel V Kalinovsky; Igor I Doronin; Sergey M Deyev; Roman V Kholodenko
Journal:  J Immunol Res       Date:  2018-07-11       Impact factor: 4.818

Review 6.  Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology.

Authors:  Esteban Javier Rozen; Jason Matthew Shohet
Journal:  Cancer Metastasis Rev       Date:  2021-10-30       Impact factor: 9.264

7.  Expression of c-kit protein in cancer vs. normal breast tissue.

Authors:  Abdolhassan Talaiezadeh; Seyed Nematollah Jazayeri; Jamal Nateghi
Journal:  Contemp Oncol (Pozn)       Date:  2012-09-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.